Oligopeptide Combi-Therapy of (resistant) steroidal cancers
Proprietary decapeptide drugs developed for tumor therapy of steroidal cancers (breast/mamma, ovarial, endometrial, prostate) and malignant melanoma. Mono-therapy or combi-therapy with current drugs possible due to huge synergism. Resensitization of tamoxifen resistant tumors and therapy of triple-negative breast cancer.
Further Information: PDF
MBM ScienceBridge GmbH
Phone: (0551) 30724-151
Contact
Dr. Jens-Peter Horst
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Machine learning algorithm reveals long-theorized glass phase in crystal
Scientists have found evidence of an elusive, glassy phase of matter that emerges when a crystal’s perfect internal pattern is disrupted. X-ray technology and machine learning converge to shed light…
Mapping plant functional diversity from space
HKU ecologists revolutionize ecosystem monitoring with novel field-satellite integration. An international team of researchers, led by Professor Jin WU from the School of Biological Sciences at The University of Hong…
Inverters with constant full load capability
…enable an increase in the performance of electric drives. Overheating components significantly limit the performance of drivetrains in electric vehicles. Inverters in particular are subject to a high thermal load,…
